Extens promotes Morgane Decultieux to Investment Director
Extens, the investment fund specializing in healthcare software and data, continues its development and promotes Morgane Decultieux from Associate to Investment Director.
Morgane was recently involved in the strategic merger between pharmTech specialists Clardian and Qairn to create Ubaq (dematerialized regulatory process solution for the healthcare industry). She joined Extens in January 2021 as an Analyst before being promoted to Associate in January 2022. To date, Morgane has taken part in 6 investments, 3 add-ons, and one exit. She also serves on the boards of Coptis, DigitecPharma, Kayentis, Sofia, and Ubaq.
Morgane previously worked for Mérieux Equity Partners, and then in IQVIA’s consulting division, before joining Wefight.
Morgane is a Doctor in Pharmacy (PharmD) from the Université Claude Bernard Lyon 1 and holds an MSc in Finance from EM Lyon.